tbuckley/cabot-search huggingface dataset:
The Life of Pasteur.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Juan A. Pineda, José A. García‐García
Journal: Hepatology (2005)

We appreciate the comments of Brady et al. related to our recent study in which we analyzed the survival of hepatitis C virus (HCV)-infected patients with decompensated cirrhosis.1 They raise two very interesting issues. First, they suggest that highly active antiretroviral therapy (HAART) could be associated with an increased risk of death in HIV/HCV-coinfected patients with advanced liver disease. They support such a hypothesis based on the fact that antiretroviral therapy–induced hepatotoxicity may lead to an enhancement of liver damage. However, an acceleration of liver fibrosis progression in HIV/HCV-coinfected patients has been associated with immunosupression.2 Consequently, immune restoration is expected to influence positively the evolution of liver disease after starting HAART. In our study, 34 (34%) of the 100 HIV-infected deceased patients took HAART, whereas 43 (54%) of 80 coinfected survivors were under HAART (P = .008). This seemingly protective factor is in agreement with other studies in which an association between HAART and a lower liver-related mortality has been observed.3, 4 Second, Brady et al. state that HIV-related central nervous system damage might have been misinterpreted as hepatic encephalopathy (HE) because of the diagnosis criteria we used. However, we think this is very unlikely. In fact, in our hospitals, cerebral computed tomography, brain magnetic resonance imaging, and, in most cases, studies of cerebrospinal fluid are included in routine diagnostic examinations of HIV-infected patients with neurological symptoms. Moreover, measurement of plasma ammonia levels and electroencephalography help us to support the diagnosis of HE. Finally, although there are no specific clinical manifestations of this disorder, symptoms and signs included in a commonly used grading system of HE are required to establish such a diagnosis.5 Thus it is unlikely that a false diagnosis of HE in this population would have occurred. We agree with Brady and colleagues that prospective studies on the interplay of HIV/HCV infection on liver disease are needed. We are pleased that our study stimulates such questions. Juan A. Pineda Ph.D.*, José A. García-García M.D.*, * Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain.
Ocular examinations in outpatients given long-term chlorpromazine therapy
Authors: L. K. Sarin
Journal: JAMA (1966)

GRANULAR LESIONS of the lens and cornea can occur in patients receiving long-term therapy with chlorpromazine and other phenothiazines, usually at high dosages.<sup>1-3</sup>These lesions, which have been described in detail<sup>4,5</sup>rarely result in visual impairment. They occur in most patients who have abnormal skin pigmentation and are often more advanced than the lesions that occur in patients who do not have abnormal skin pigmentation. Their development seems to be related to total dosage and duration of treatment. DeLong and Prien estimate the incidence of eye lesions in such patients to be approximately 20%.<sup>6</sup>To determine whether eye lesions can also occur with long-term therapy at low and moderate dosages, 44 outpatients were studied. <h3>Material and Methods</h3> This series consisted of 28 women and 16 men, either private outpatients or outpatients at the Sidney Hillman Medical Center. Eighteen were psychotics and 26 were psychoneurotics. Their average age
Publication of Survey Results of Assessment of State Health Agencies' Readiness for 2000
Journal: JAMA (1999)

Following publication of the results of a CDC assessment of the readiness for the year 2000 (Y2K) of state health agencies, CDC conducted a follow-up survey during June-August 1999 in which 47 states and the District of Columbia-covering 98.7% of the U.S. population-responded. Overall, responding states are 99% complete with Y2K assessment and 90% complete with Y2K readiness. Additional information from the states and trends from the initial to the follow-up survey identify no significant Y2K readiness vulnerabilities in critical public health functions. Complete results of this survey are available on the World-Wide Web at http://www.cdc.gov/y2k/y2kssurvey.htm++ + and from the Information Resources Management Office, CDC, Mailstop D45, 1600 Clifton Rd., N.E., Atlanta, GA 30333. CDC continues to work with states on Y2K readiness, including identifying and communicating Y2K issues that may occur during the transition to 2000.
New treatment schedule with improved survival in childhood leukemia. Intermittent parenteral vs daily oral administration of methotrexate for maintenance of induced remission. Acute leukemia group B
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).
Authors: Lowell L. Hart, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, Martine J. Piccart-Gebhart, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Mona El-Hashimy, Shantha Rao, Ashok Panneerselvam, Tanya Taran, Gabriel N. Hortobagyi, Tarek Sahmoud, David Edward Lebwohl, Michael Gnant
Journal: Journal of Clinical Oncology (2012)

102 Background: BOLERO-2, a multinational, double-blind, placebo-controlled, phase III study in postmenopausal women with estrogen-receptor–positive breast cancer (BC) refractory to nonsteroidal aromatase inhibitors (NSAIs), showed significant clinical benefits with the addition of EVE to exemestane (EXE) (Baselga J et al. NEJM2011 Epub). As bone resorption is an important factor in BC mets, it is interesting to study bone-related effects of EVE. In preclinical studies, mTOR inhibition was associated with decreased osteoclast survival and activity. Exploratory analyses in BOLERO-2 evaluated the effects of EVE vs placebo (PBO) on BM levels and BC progression in bone in pts with bone mets at baseline. Methods: Eligible pts were treated with EXE (25 mg once daily) and randomized (2:1) to EVE (10 mg once daily) or PBO. Bone turnover markers (BMs) were exploratory endpoints analyzed at 6 and 12 wks after treatment initiation and included bone-specific alkaline phosphatase, amino-terminal propeptide of type I collagen, and C-terminal cross-linking telopeptide of type I collagen. Progressive disease in bone (PDB) was defined as worsening of a preexisting bone lesion or a new bone lesion. Results: Baseline disease characteristics, including bone mets at baseline (n = 370, 76% EVE vs n = 184, 77% PBO), were well balanced between arms (N = 724), and baseline bisphosphonate use was not (44% EVE vs 55% PBO). At 12.5 mo median follow-up, progression-free survival (primary endpoint), overall response rate, and clinical benefit rate (p &lt; 0.0001, all) were significantly higher with EVE (n = 485) vs PBO (n = 239). BM levels at 6 and 12 wks increased vs baseline with PBO but decreased with EVE. The cumulative incidence rate of BC PBD was lower for EVE vs PBO at day 60 (3.03% vs 6.16%, respectively), and this trend was sustained beyond 6 months. Updated results will be presented. All bone-related adverse events reported were grade 1-2 and occurred with similar frequency in EVE (2.9%)- and PBO (3.8%)-treated patients. Conclusions: Exploratory analyses from BOLERO-2 suggest that adding EVE has beneficial effects on bone turnover and BC progression in bone in pts receiving EXE therapy for NSAI-refractory BC.
Request for Abstracts
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
William Stewart Halsted (1852-1922) Surgeon of the "Hopkins Four"
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group
Authors: Jordi Ribera, Lurdes Zamora, Mireia Morgades, Ramon Guardia, Josep Sarrá, Inés Gómez-Seguí, Pau Montesinos, Marta Pratcorona, Jordi Esteve, Josep F. Nomdedeu, Salut Brunet, Mar Tormo, Maria Collado, Joaquín Martínez, Pilar Martinez-Sanchez, Jesus Maria Hernández-Rivas, Marcos González, José González-Campos, Pablo Trujillo, Pere Barba, Neus Ruiz-Xivillé, Isabel Granada, Silvia Marce, Marta Cabezón, Eulàlia Genescà, Francesc Solé, Jordi Juncà, Fuensanta Millá, Evarist Feliu, Josep-Maria Ribera
Journal: Blood (2013)
Direct mailing as a means of disseminating NIH consensus statements. A comparison with current techniques
Authors: I. Jacoby
Journal: JAMA (1986)

The Office of Medical Applications of Research of the National Institutes of Health conducted a survey to evaluate the effectiveness of mass mailing of consensus statements as compared with traditional dissemination methods. The consensus statement on osteoporosis, published earlier in<i>JAMA</i>, was selected for study. Physicians (N=695) within each of five relevant specialties in two comparable metropolitan areas were surveyed. Findings suggest that while a small but significant increase of awareness resulted from direct mailing, this increase should be weighed against costs and effectiveness of other methods. (<i>JAMA</i>1986;255:1328-1330)
Medicine
Authors: James A. Kruse
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic rejection.
Authors: A J Matas, J F Burke, G A DeVault, A Monaco, J D Pirsch
Journal: Journal of the American Society of Nephrology (1994)

Current immunosuppressive protocols have significantly decreased graft loss to acute rejection but have had no effect on graft loss to chronic rejection. Recently, attention has been focused on the prevention and management of chronic rejection. Centers must come to a uniform definition of this phenomenon so that studies can be compared. It is believed that the definition should include both a typical clinical course and a definitive biopsy. For kidney transplant recipients, the major risk factor for the development of chronic rejection appears to be a previous acute rejection episode. Other important risk factors include low-dose maintenance immunosuppression and previous infection. Noncompliance probably plays a role in some patients. For extrarenal transplant recipients, chronic rejection has been associated with cytomegalovirus infection and/or HLA-DR matching. Immunoregulatory processes posttransplant may modify or attenuate the development of chronic rejection. Large, prospective clinical studies are required to further elucidate risk factors and to determine the effect of intervention.
Do these primates have AIDS?
Authors: C. Macek
Journal: JAMA (1983)

Both a condition resembling acquired immunodeficiency syndrome (AIDS) in humans and an unusual number of certain malignant neoplasms have occurred spontaneously in two primate colonies on opposite coasts of the United States. While the relationship between what some are calling simian AIDS and the human disease is unknown, it's possible that a primate model for human AIDS soon may be available. The outbreaks occurred in several macaque monkey species at both the New England Primate Research Center in Southborough, Mass, and the California Primate Research Center at the University of California, Davis. The primary species affected were cyclopis monkeys (<i>Macaca cyclopis</i>) at the New England center and rhesus monkeys (<i>Macaca mulatta</i>) at the California center. Most of the monkeys were being raised for future research purposes. The investigators discounted any effects of treatments on those currently being used in research protocols. "In recent years it became apparent that there were
THE MENOPAUSE.
Authors: BYRON ROBINSON
Journal: JAMA (1894)

Menstruation belongs distinctly to the tubes and uterus. It is a regular rhythmic action. It is controlled by the automatic menstrual ganglia situated in the walls of the tubes and uterus. These rhythmic little brains manifest themselves to the observer by circulatory change and increased motion. Menstruation might be named tubai motion. By direct observation in man and animals, I have noted the following midway between the monthly, or at times far remote from œstrus or rutting. The tubes and uterus are of quite a pale pink color. In short they are not congested, and still. But at the menstrual period or the season of œstrus the tubes and uterus are congested and in active peristaltic motion. The tubes are of a dark blue color from their dilated vessels being full of blood. The congestion of the uterus is intense but not so manifest as the tubes. The tubes are
Traffic safety experts prescribe treatment, sanctions to improve driving
Authors: T. B. Cole
Journal: JAMA (1995)

DO CARS kill people, or is it people who do the killing? Both, say the physicians, epidemiologists, engineers, and others who attended the 39th Annual Conference of the Association for the Advancement of Automotive Medicine (AAAM), held in Chicago, Ill. The guiding philosophy of the AAAM is that both vehicle construction and personal behavior can be modified to reduce morbidity and mortality on the nation's roadways. Behavioral modification has proved to be the more difficult task. Advances are both helped and hindered by the interdependence of man and machine. "Intelligent" safety restraint systems can sense when to deploy, slacken, and hold fast, but fewer than three fourths of drivers and passengers buckle up. Trauma systems can triage, transport, and treat injured patients so effectively that preventable mortality is reduced by as much as 30%, but the same patients may be injured again and again as a result of alcoholism. Ultimately,
A cholestatic pattern predicts liver outcomes in patients with non-alcoholic fatty liver disease
Authors: Grazia Pennisi, Rosaria Maria Pipitone, Stefania Grimaudo, Federica Spatola, Vincenzo Di Martino, Vincenza Calvaruso, Calogero Camma, Vito Di Marco, Antonio Craxi, Salvatore Petta
Journal: Journal of Hepatology (2020)
‘Multicentre study evaluating matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically isolated Elizabethkingia species and analysis of antimicrobial susceptibility’ – Author's reply
Authors: Y.-H. Cheng, C.-L. Perng, M.-J. Jian, Y.-H. Cheng, S.-Y. Lee, J.-R. Sun, H.-S. Shang
Journal: Clinical Microbiology and Infection (2018)
Medial Blepharorrhaphy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Atlas of Clinical Medicine.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal